<SEC-DOCUMENT>0001213900-25-082920.txt : 20250902
<SEC-HEADER>0001213900-25-082920.hdr.sgml : 20250902
<ACCEPTANCE-DATETIME>20250902080003
ACCESSION NUMBER:		0001213900-25-082920
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250902
FILED AS OF DATE:		20250902
DATE AS OF CHANGE:		20250902

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		251282988

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0255478-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>





     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
6-K</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO RULE 13a-16 OR 15d-163</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the month of September   2025</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alterity
Therapeutics Limited</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</a>) and our
Registration Statements on Form F-3 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</a>)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALTERITY
THERAPEUTICS LIMITED</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
development stage enterprise)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">99.1</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea025547801ex99-1_alterity.htm">Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC</A></P></TD></TR>
  </TABLE>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>SIGNATURE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Alterity Therapeutics Limited</b></font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">By:</font></td>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">/s/ Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Chairman</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
September 2, 2025</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025547801ex99-1_alterity.htm
<DESCRIPTION>ALTERITY THERAPEUTICS FILED FORM 20-F AND XBRL DATA WITH SEC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alterity Therapeutics Filed Form 20-F and XBRL
data with the SEC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
&ndash; 2 September 2025:</B> Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;), a
biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced&nbsp;that it
has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year ended June 30, 2025 with the
US Securities and Exchange Commission (SEC). The annual report is available on the company website https://alteritytherapeutics.com.
Shareholders may receive a hard copy of the annual report free of charge upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company has also filed the XBRL interactive
data with the SEC and this is available via the company website at https://alteritytherapeutics.com/investor-overview/press-releases/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Alterity Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living&nbsp;with neurodegenerative diseases. The Company is initially focused
on developing disease modifying therapies in Parkinson&rsquo;s disease and related disorders. Alterity has demonstrated clinically meaningful
efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple
System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label
Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds
to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California,
USA. For further information please visit the Company&rsquo;s website at www.alteritytherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorisation &amp; Additional information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor and Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ana Luiza Harrop</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+61 452 510 255</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">remy.bernarda@iradvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;evidences&rdquo; and &ldquo;estimates,&rdquo; and
other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements are described in the sections titled &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including,
but not limited to the following: statements relating to the Company&rsquo;s drug development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company&rsquo;s drug development program, including, but not limited to, ATH434, and any other
statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks
and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing
of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future
sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&rsquo;s drug compounds, including, but
not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company&rsquo;s
intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s patent rights and the uncertainty
of the Company freedom to operate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Any forward-looking statement made by us in
this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as
a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pc; margin-bottom: 0pc; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V -T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ K
M\O?^"DG[9?B+]G/POIO@#X>VUQ:^/O'NDW%RGBLJ1%X7T226]L6N-+X/F:]<
M2V=T+>X/&E0Q?:T1KJ:UEMOJ[5OVNO@#HGQ2M_@_J?CRQMO&%Q=)IS%HI3H=
MKJLIV1Z3>:X!]AM[UI<6[[W^S07A^Q7-S!>!H%;^U%^R_P" ?VH_A]<^$?%<
M$=CKME'/<>$/%\%NDNI>&]4=!M8<H]UI5VZ1)JFFF6-;F)5E@EMKZ"UNX/L^
M&*6 R#B3A_'<:Y)CYY%6E3QOL<1AL10ABL-426%Q\*=2E!YA@:%=T\16P])V
MQ=&#I)M3A'$_G'&>(S+BW@_BK+/#7B?*8<389U,LEBL'CL)BI8'&49-X[*:M
M?#UZ_P#9.98G#*MA*.*K0Y\#6FZMHRA.M@OY;_V7_P!MOXJ_LR_$V3Q-;ZIJ
M/BWPQXJU=9?'_A+5]1N9K?Q&UY,HN-3%Q.URUMXBC),EGK(1[A7Q#=+=V4]W
M:W/]@/@SQ5IWCKPAX6\:Z.EU%I/B[P[HWB73([Z$V]['8:YIUOJ=HEW 2WDW
M"07,:S1AF"2!@K, &/\ /S^P]_P3/M?$'Q.\=^*OCHVGZQX9^#WQ&UGP+;>$
MK24W%EXM\5>'5L[FZGU1FCC+>%[>#4+*4P;4EUQYA:7"6ME!?6U]^WWQQ^/O
MPB_9E\!'QQ\5?$=GX4\-VTD.F:79V]N;C4=4NA&!#I7A_1;1?/O)8;=#(\<$
M:6UE:1M/<RV]NA<?HWC3C^&.(N),KP7".73QF>QI4Z&8XO+,/)4LR>(P^$K9
M9@J.$HT(U,7C,+0K4U+%0HPY</.A@KUHX95,)^7_ $=LJXPX6X,S/&<;X_\
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MO)(%\1>"?$:P1S7GAWQ%9PR2"&ZA619K.\B+V.K6$D&HZ?--;3 K])U^*8[
M8W*\9BLNS'"U\#CL%6J8?%X3%4I4<1AZ]*7+.G5IS2E&2=FG[T9QE"I3G4IU
M*=2I^Q8/&87,,+A\=@J]+%83%T:>(PV(HS4Z5:C5BITZD)*UU)/9J,HR4H3C
M"<)P@5_'O_P=L_MPM\._@'\*OV&O!>KF'Q5\>=6M_B7\4X;2X>.>T^%7@;4R
M/"^C7@AFC<0^,?'MJ=1B1E*RQ?#^ZMYOW%X5D_KYU75--T/3-2UK6+ZUTS2-
M'L+S5-5U*^F2VLM/TW3[>2[OKZ\N)66*"UM+6&6XN)I&5(HHW=V"J37^4/\
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M/O)1G&4W)3LY)QBM8JPTN:<VYNT9)**=K62W2_7S/XF_^"R?_!1K]M[]GO\
MX+2_ 7]G;X,_M%>./A_\%/%D?[+K:]\/M&C\/MHNH_\ ":_$&YT;Q3YQO]%O
M+X?VS8(L%T4NU^08B\LC(^C?^#HCP7_P42N?A#KGQ#^"'Q!.@?L)^'_@OH^B
M_M-^#T\4^&]/D\2>)-9^+-MIVDE?#E]I\GB+55D;5O"$4TNDW\4(M[:831+'
M!<F?\F_^"^X8_P#!P?\ LRGD@0?L9 ?^'6O2<#KWY(K^J_\ X.!/#VL^)O\
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MM'\-Z_J?B72H)M(T+4K33[F6'5=8OY9+B:%IIHYEBD<K#%L_3BOQ3_X)O_\
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+R:32V35U;6X?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
